Dual targeting of CDK4/6 and Bcl-2 exhibits a potent antitumor effect on mantle cell lymphoma

,

[1]  Xinghuan Wang,et al.  WFDC2 suppresses prostate cancer metastasis by modulating EGFR signaling inactivation , 2020, Cell Death & Disease.

[2]  S. Stilgenbauer,et al.  Clinical activity of abemaciclib in patients with relapsed or refractory mantle cell lymphoma - a phase II study. , 2020, Haematologica.

[3]  Jing Wang,et al.  Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma , 2018, Molecular Cancer Therapeutics.

[4]  S. Lade,et al.  Ibrutinib plus Venetoclax for the Treatment of Mantle‐Cell Lymphoma , 2018, The New England journal of medicine.

[5]  A. Arrigo.  Mammalian HspB1 (Hsp27) is a molecular sensor linked to the physiology and environment of the cell , 2017, Cell Stress and Chaperones.

[6]  P. Iversen,et al.  Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine , 2014, Investigational New Drugs.

[7]  Richard G. Moore,et al.  HE4 (WFDC2) gene overexpression promotes ovarian tumor growth , 2014, Scientific Reports.

[8]  A. Wiestner,et al.  Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. , 2011, Blood.

[9]  Xavier Estivill,et al.  Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. , 2009, Blood.

[10]  E. Campo,et al.  Secondary genomic alterations in non-Hodgkin’s lymphomas: tumor-specific profiles with impact on clinical behavior , 2008, Haematologica.

[11]  E. Campo,et al.  Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics , 2007, Nature Reviews Cancer.

[12]  A. Rosenwald,et al.  Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Landry,et al.  Increased survival after treatments with anticancer agents of Chinese hamster cells expressing the human Mr 27,000 heat shock protein. , 1991, Cancer research.

[14]  V. Jiang,et al.  PIK-75 overcomes venetoclax resistance via blocking PI3K-AKT signaling and MCL-1 expression in mantle cell lymphoma. , 2022, American journal of cancer research.